...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride.
【24h】

Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride.

机译：来自J-PULSE多中心注册表的报告显示，使用盐酸硝苯卡那治疗的抗休克型院外心脏骤停患者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Nifekalant hydrochloride (NIF) is an intravenous class-III antiarrhythmic agent that purely blocks the K(+)-channel without inhibiting beta-adrenergic receptors. The present study was designed to investigate the feasibility of NIF as a life-saving therapy for out-of-hospital ventricular fibrillation (VF). METHODS AND RESULTS: The Japanese Population-based Utstein-style study with basic and advanced Life Support Education study was a multi-center registry study with 4 participating institutes located at the northern urban area of Osaka, Japan. Eligible patients were those treated with NIF because of out-of-hospital VF refractory to 3 or more precordial shocks and intravenous epinephrine. Between February 2006 and February 2007, 17 patients were enrolled for the study. The time from a call for emergency medical service to the first shock was 12(6-26)min. The time from the first shock to the NIF administration was 25.5(9-264)min and the usage dose of NIF was 25(15-210)mg. When excluding 3 patients in whom percutaneous extracorporeal membrane oxygenation was applied before NIF administration, the rate of return of spontaneous circulation was 86% and the rate of admission alive to the hospital was 79%. One patient developed torsade de pointes. CONCLUSIONS: Intravenous administration of NIF seems to be feasible as a potential therapy for advanced cardiac life-support in patients with out-of-hospital VF, and therefore further study is warranted.
机译：背景：硝苯卡仑盐酸盐（NIF）是一种静脉注射的III类抗心律失常药，它在不抑制β-肾上腺素能受体的情况下完全阻断K（+）通道。本研究旨在调查NIF作为医院外心室纤颤（VF）挽救生命的治疗方法的可行性。方法和结果：日本人口为基础的乌特斯坦式研究，包括基础和高级生命支持教育研究，是一项多中心注册研究，由位于日本大阪北部市区的4个参与机构组成。合格的患者是因院外VF对3次或更多次心前区电击难治和静脉内肾上腺素难治而接受NIF治疗的患者。在2006年2月至2007年2月之间，共有17名患者入选该研究。从要求紧急医疗服务到第一次电击的时间为12（6-26）分钟。从第一次休克到服用NIF的时间为25.5（9-264）min，NIF的使用剂量为25（15-210）mg。当排除3例在NIF给药前应用经皮体外膜氧合的患者时，自发性循环的返还率为86％，活着的住院率为79％。一名患者发展了尖尖扭转综合征。结论：静脉内给予NIF作为院外VF患者晚期心脏生命支持的潜在疗法似乎是可行的，因此有必要进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号